Opinion: Building the perfect wearable for clinical trials
The pace of innovation in wearable technology has never been faster. As often as once…
Category: Opinions Plus
Opinion: STAT+: Three steps toward creating a functioning U.S. biosimilars market
The development of safe, effective, and innovative biologic medicines is one of modern medicine’s far-reaching…
Opinion: STAT+: Unprecedented development of Covid-19 vaccines, treatments points to biopharma’s future
Business as usual has not been the mantra for companies developing Covid-19 vaccines and drugs….
Opinion: STAT+: A Biden-Harris Biomanufacturing Initiative could increase supplies of vaccines, therapeutics in one fell swoop
The coronavirus pandemic is generating pressure on the manufacturing of vaccines and therapeutics. Every day…
Opinion: STAT+: Making pharma’s post-Covid-19 future faster and smarter
There’s nothing like a global pandemic to force a reimagining of one’s business. What it…
Opinion: STAT+: Create a U.S. Institute of Health Technology Assessment to preserve innovation and control costs
The public outcry to “do something” about health care spending keeps growing, but fear about…
Opinion: STAT+: Talent, culture, and ethics are all necessary ingredients in the biotech recipe for success
Even as hopes soar that soon-to-be-distributed Covid-19 vaccines will help quench the global coronavirus pandemic,…
Opinion: STAT+: In biopharma mergers and acquisitions, managing regulatory compliance early protects return on investment
Mergers and acquisitions have long been a vehicle for growth in the pharmaceutical industry. They…
Opinion: STAT Plus: Why medtech is a different beast than biotech in the life sciences pack
Biotech innovations dominate the life science news cycle — think CRISPR for gene editing or…